Literature DB >> 9407632

Whole brain radiotherapy in the treatment of metastatic brain tumors.

S S Vermeulen1.   

Abstract

Previous prospective and retrospective trials have failed to demonstrate the best treatment approach for patients with brain metastases. As a result, fractionated whole brain radiotherapy (WBRT) has been the mainstay of treatment for several decades. However, with improved surgical techniques and the advent of radiosurgical procedures to treat single and multiple metastases, the continued value of WBRT is in question. This is particularly true in the treatment of a favorable patient subset where the risks of long-term morbidity need to be addressed. This article reviews the trials of the Radiation Therapy Oncology Group (RTOG) and other select radiotherapy brain metastases trials, and compares their morbidities and outcomes to surgical and radiosurgical techniques. It is unfortunate that the inherent selection bias in most retrospective studies makes comparisons difficult. Therefore, to better understand the roles of WBRT, surgery, and radiosurgery in the treatment of brain metastases, additional randomized studies need to be conducted on homogeneous patient groups.

Entities:  

Mesh:

Year:  1998        PMID: 9407632     DOI: 10.1002/(sici)1098-2388(199801/02)14:1<64::aid-ssu8>3.0.co;2-0

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  4 in total

Review 1.  Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.

Authors:  Tyler Lazaro; Priscilla K Brastianos
Journal:  CNS Oncol       Date:  2017-04

Review 2.  Brain metastases.

Authors:  P Y Wen; J S Loeffler
Journal:  Curr Treat Options Oncol       Date:  2000-12

Review 3.  Analgesia for patients with advanced disease: I.

Authors:  E J Hall; N P Sykes
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

4.  Whole brain radiation therapy in management of brain metastasis: results and prognostic factors.

Authors:  Elisa Y Saito; Gustavo A Viani; Robson Ferrigno; Ricardo A Nakamura; Paulo E Novaes; Cassio A Pellizzon; Ricardo C Fogaroli; Maria A Conte; Joao V Salvajoli
Journal:  Radiat Oncol       Date:  2006-06-29       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.